The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1636
November 1, 2021
View Complete Issue         Table of Contents 2019 
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
November 1, 2021 (Issue: 1636)
The FDA has approved an expansion of the peripheral artery disease (PAD) indication for the oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently undergone a lower extremity...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
Article code: 1636c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.